Action over generic Lipitor may subject FDA to congressional probe

12/2/2012 | Pharmalot.com

The FDA's disclosure that a shortage of a generic version of cholesterol drug Lipitor is "not anticipated" may be an invitation for Congress to take up work on the drug-shortage legislation and investigate the FDA for allowing Ranbaxy Laboratories to produce and sell a generic Lipitor, RPM Report's Michael McCaughan said. Ranaxby's issues with production raise questions whether the FDA bargained hard enough if patient safety and the supply chain's integrity were the top goals.

View Full Article in:

Pharmalot.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC
Manager/Senior Manager, Health Economist
Avalere Health
Washington, DC
Director, Health Services Analytics
Avalere Health
Washington, DC
Director/Vice President. Health Actuary
Avalere Health
Washington, DC
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD